Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study, published ...
Int Ophthalmol Clin. 2014;54(1):27-41. Much of the data supporting weight loss as treatment for IIH comes from retrospective studies or class III evidence. There has been a long-standing need for ...
Three neuro-ophthalmologists at the John A. Moran Eye Center, University of Utah, participated in a recent NIH-funded study that revealed the use of an inexpensive glaucoma drug (acetazolamide), when ...
Please provide your email address to receive an email when new articles are posted on . AUSTIN, Texas — Venous manometry and neuroimaging may provide additional value when diagnosing patients who do ...
The study goal was to identify risk factors for progressive visual field loss among participants with idiopathic intracranial hypertension and mild visual loss in the Idiopathic Intracranial ...
GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema. (HealthDay News) — For patients with idiopathic intracranial ...
Doctors think they've figured out a way to predict who might lose vision due to a high brain pressure disorder. Idiopathic intracranial hypertension occurs when there's unexplained pressure buildup in ...
Glaucoma Drug, Plus Only 5-10 Percent Weight Loss Helps Restore Vision Loss to Patients with Idiopathic Intracranial Hypertension (IIH) National Institutes of Health (NIH)-Funded Study Published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback